sub:assertion {
d:DB01553 v:identifier "DB01553" ;
v:namespace "drugbank" ;
v:uri "http://bio2rdf.org/drugbank:DB01553" ;
v:x-identifiers.org <
http://identifiers.org/drugbank/DB01553> ;
dv:drugbank-id "DB01553" ;
dv:x-atc <
http://bio2rdf.org/atc:N05BA22> ;
dv:x-cas <
http://bio2rdf.org/cas:24166-13-0> ;
dv:x-chemspider <
http://bio2rdf.org/chemspider:2714> ;
dv:x-kegg <
http://bio2rdf.org/kegg:D01268> ;
dv:x-pubchemcompound <
http://bio2rdf.org/pubchem.compound:2816> ;
dv:x-pubchemsubstance <
http://bio2rdf.org/pubchem.substance:46505281> ;
dv:x-wikipedia <
http://bio2rdf.org/wikipedia:Cloxazolam> ;
dct:description """Cloxazolam is a benzodiazepine with anxiolytic, sedative/hypnotic, muscle relaxant, and antiepileptic effects. [3] It is marketed in the Argentina, Australia, Portugal, Belgium, Switzerland, Luxembourg, Germany, Taiwan and Japan -- mainly for anti-anxiety. The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. [3]
Although less commonly noted, it has also been reported as clinically effective in the treatment of depression, schizophrenia, and neurosis. [4] As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness. [3]"""@en ;
dct:identifier "drugbank:DB01553" ;
dct:title "Cloxazolam"@en ;
a dv:Drug ;
rdfs:label "Cloxazolam [drugbank:DB01553]"@en ;
rdfs:seeAlso <
http://www.drugbank.ca/drugs/DB01553> , <
http://www.drugs.com/international/cloxazolam.html> .
}